Type I interferons in anticancer immunity

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474

Innate and adaptive immune cells in the tumor microenvironment

Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148

Virus interference. I. the interferon

Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451

The Three Es of Cancer Immunoediting

Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,235

Type I interferons in infectious disease

McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors

Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917

Executioner caspases restrict mitochondrial RNA-driven Type I IFN induction during chemotherapy-induced apoptosis

Killarney, S. T., Washart, R., Soderquist, R. S., Hoj, J. P., Lebhar, J., Lin, K., & Wood, K. C. (2023) · Nature Communications · doi:10.1038/s41467-023-37146-z · Cited by 44

hnRNPM protects against the dsRNA-mediated interferon response by repressing LINE-associated cryptic splicing

Zheng, R., Dunlap, M., Bobkov, G. O. M., Gonzalez‐Figueroa, C., Patel, K. J., Lyu, J., Harvey, S. E., Chan, T. W., Quinones-Valdez, G., Choudhury, M., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.05.004 · Cited by 44

Insights into the Mechanisms of Action of Akkermansia muciniphila in the Treatment of Non-Communicable Diseases

Mruk-Mazurkiewicz, H., Kulaszyńska, M., Czarnecka, W., Podkówka, A., Ekstedt, N., Zawodny, P., Wierzbicka-Woś, A., Marlicz, W. M., Skupin, B., Stachowska, E., et al. (2024) · Nutrients · doi:10.3390/nu16111695 · Cited by 41

Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer

Fend, L., Rusakiewicz, S., Adam, J., Bastien, B., Caignard, A., Messaoudene, M., Iribarren, C., Cremer, I., Marabelle, A., Borg, C., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1163456 · Cited by 41

The Interaction Between Human Papillomaviruses and the Stromal Microenvironment

Woodby, B. L., Scott, M. L., & Bodily, J. M. (2016) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2016.09.003 · Cited by 41

Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer

Aljohani, A., Joseph, C., Kurozumi, S., Mohammed, O. J., Miligy, I. M., Green, A. R., & Rakha, E. A. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05646-x · Cited by 41

A recombinant oncolytic Newcastle virus expressing MIP-3α promotes systemic antitumor immunity

Huang, F., Wang, J., Dai, S.-Z., Lin, Y., Sun, Y., Zhang, L., Lu, Z., Cao, R. Y., & Tan, G. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000330 · Cited by 41

Self RNA Sensing by RIG-I–like Receptors in Viral Infection and Sterile Inflammation

Stok, J. E., Quiroz, M. E. V., & van der Veen, A. G. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000488 · Cited by 41

Impact of cancer evolution on immune surveillance and checkpoint inhibitor response

Wu, Y., Biswas, D., & Swanton, C. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.013 · Cited by 43

Comprehensive description of the current breast cancer microenvironment advancements via single-cell analysis

Yan, X., Xie, Y., Yang, F., Hua, Y., Zeng, T., Sun, C., Yang, M., Huang, X., Wu, H., Fu, Z., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01949-z · Cited by 41

Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol

Geboers, B., Timmer, F. E. F., Ruarus, A. H., Pouw, J. E. E., Schouten, E., Bakker, J., Puijk, R. S., Nieuwenhuizen, S., Dijkstra, M., van den Tol, M., et al. (2021) · Cancers · doi:10.3390/cancers13153902 · Cited by 41

Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growth

Lasfar, A., de la Torre, A., Abushahba, W., Cohen-Solal, K., Castaneda, I., Yuan, Y., Reuhl, K. R., Zloza, A., Raveche, E. S., Laskin, D. L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10272 · Cited by 42

Signaling by Type I Interferons in Immune Cells: Disease Consequences

Ζαννίκου, Μ., Fish, E. N., & Platanias, L. C. (2024) · Cancers · doi:10.3390/cancers16081600 · Cited by 43

NAT10-mediated upregulation of GAS5 facilitates immune cell infiltration in non-small cell lung cancer via the MYBBP1A-p53/IRF1/type I interferon signaling axis

Wang, Z., Luo, J., Huang, H., Wang, L., Lv, T., Wang, Z., Li, C., Wang, Y., Liu, J., Cheng, Q., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01997-2 · Cited by 40

Rb selectively inhibits innate IFN-β production by enhancing deacetylation of IFN-β promoter through HDAC1 and HDAC8

Meng, J., Liu, X., Zhang, P., Li, D., Xu, S., Zhou, Q., Guo, M., Huai, W., Chen, X., Wang, Q., et al. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.05.012 · Cited by 42

Respiratory syncytial virus non-structural protein 1 facilitates virus replication through miR-29a-mediated inhibition of interferon-α receptor

Zhang, Y., Yang, L., Wang, H., Zhang, G., & Sun, X. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.142 · Cited by 40

Getting “Inside” Type I IFNs: Type I IFNs in Intracellular Bacterial Infections

Snyder, D. T., Hedges, J. F., & Jutila, M. A. (2017) · Journal of Immunology Research · doi:10.1155/2017/9361802 · Cited by 43

Toll‐like receptor 3 signal augments radiation‐induced tumor growth retardation in a murine model

Yoshida, S., Shime, H., Takeda, Y., Nam, J., Takashima, K., Matsumoto, M., Shirato, H., Kasahara, M., & Seya, T. (2018) · Cancer Science · doi:10.1111/cas.13543 · Cited by 40

Activation of human CD141+ and CD1c+ dendritic cells in vivo with combined TLR3 and TLR7/8 ligation

Pearson, F. E., Chang, K., Minoda, Y., Rojas, I. L., Haigh, O. L., Daraj, G., Tullett, K. M., & Radford, K. J. (2018) · Immunology and Cell Biology · doi:10.1111/imcb.12009 · Cited by 40

Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives

Testori, A., Ribero, S., Indini, A., & Mandalà, M. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00456-4 · Cited by 41

Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma

Monti, M., Consoli, F., Vescovi, R., Bugatti, M., & Vermi, W. (2020) · Cells · doi:10.3390/cells9020417 · Cited by 41

pH‐Responsive STING‐Activating DNA Nanovaccines for Cancer Immunotherapy

Zhang, Y., Shen, T., Zhou, S., Wang, W., Lin, S., & Zhu, G. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000083 · Cited by 40

Dendritic Cells: Behind the Scenes of T-Cell Infiltration into the Tumor Microenvironment

Lucarini, V., Melaiu, O., Tempora, P., D’Amico, S., Locatelli, F., & Fruci, D. (2021) · Cancers · doi:10.3390/cancers13030433 · Cited by 43

Cowpea Mosaic Virus Outperforms Other Members of the Secoviridae as In Situ Vaccine for Cancer Immunotherapy

Beiss, V., Mao, C., Fiering, S., & Steinmetz, N. F. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00058 · Cited by 40

STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells

Wang, L., Liang, Z., Guo, Y., Habimana, J. D. D., Ren, Y., Amissah, O. B., Mukama, O., Peng, S., Ding, X., Lv, L., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06638-1 · Cited by 42

Subversion of anticancer immunosurveillance by radiotherapy

Zitvogel, L., & Kroemer, G. (2015) · Nature Immunology · doi:10.1038/ni.3236 · Cited by 43

Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus

Oseledchyk, A., Ricca, J. M., Gigoux, M., Ko, B., Redelman‐Sidi, G., Walther, T., Liu, C., Iyer, G., Merghoub, T., Wolchok, J. D., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25614 · Cited by 39

Type I Interferon Delivery by iPSC-Derived Myeloid Cells Elicits Antitumor Immunity via XCR1+ Dendritic Cells

Tsuchiya, N., Zhang, R., Iwama, T., Ueda, N., Liu, T., Tatsumi, M., Sasaki, Y., Shimoda, R., Osako, Y., Sawada, Y., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.086 · Cited by 39

JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML

Dagher, T., Maslah, N., Edmond, V., Cassinat, B., Vainchenker, W., Giraudier, S., Pasquier, F., Verger, E., Niwa‐Kawakita, M., Lallemand-Breitenbach, V., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20201268 · Cited by 39

Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment

Accogli, T., Bruchard, M., & Végran, F. (2021) · Cancers · doi:10.3390/cancers13030373 · Cited by 43

Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications

Wanderley, C. W. S., Corrêa, T. S., Scaranti, M., Cunha, F. Q., & Barroso‐Sousa, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.816642 · Cited by 40

MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer

Alburquerque-Béjar, J. J., Navajas-Chocarro, P., Saigí, M., Ferrero-Andres, A., Morillas, J. M., Vilarrubi, A., Gómez, A., Mate, J. L., Muñoz-Mármol, A. M., Romero, O. A., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101006 · Cited by 42

Beyond binary: bridging neutrophil diversity to new therapeutic approaches in NSCLC

Horvath, L., Puschmann, C., Scheiber, A., Martowicz, A., Sturm, G., Trajanoski, Z., Wolf, D. G. F., Pircher, A., & Salcher, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.01.010 · Cited by 39

Type I IFN Receptor Signaling Controls IL7-Dependent Accumulation and Activity of Protumoral IL17A-Producing γδT Cells in Breast Cancer

Patin, E. C., Soulard, D., Fleury, S., Hassane, M., Dombrowicz, D., Faveeuw, C., Trottein, F., & Paget, C. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1416 · Cited by 38

Terminating the renewal of tumor-associated macrophages: A sialic acid-based targeted delivery strategy for cancer immunotherapy

Ding, J., Zhao, D., Hu, Y., Liu, M., Liao, X., Zhao, B., Liu, X., Deng, Y., & Song, Y. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118706 · Cited by 38

Melanoma suppression by quercein is correlated with RIG-I and type I interferon signaling

Peng, D., Chen, L., Sun, Y., Sun, L., Yin, Q., Deng, S., Niu, L., Lou, F., Wang, Z., Xu, Z., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109984 · Cited by 38

Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy

Varshney, D., Qiu, S. Y., Graf, T. P., & McHugh, K. J. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00620-x · Cited by 40

Type I Interferon Induction and Exhaustion during Viral Infection: Plasmacytoid Dendritic Cells and Emerging COVID-19 Findings

Greene, T. T., & Zúñiga, E. I. (2021) · Viruses · doi:10.3390/v13091839 · Cited by 41

Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy

Yang, Z., Sun, J. K., Lee, M. M., & Chan, M. K. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005068 · Cited by 39

Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies

Moreno, V., Calvo, E., Middleton, M. R., Barlési, F., Gaudy‐Marqueste, C., Italiano, A., Romano, E., Marabelle, A., Chartash, E., Dobrenkov, K., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03191-8 · Cited by 37

Retinoic acid signaling in development and differentiation commitment and its regulatory topology

Wu, D., Khan, F. A., Zhang, K., Pandupuspitasari, N. S., Negara, W., Guan, K., Sun, F., & Huang, C. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110773 · Cited by 37

Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod

Rozenblit, M., Hendrickx, W., Heguy, A., Chiriboga, L. A., Loomis, C. A., Ray, K., Darvishian, F., Egeblad, M., Demaria, S., Marincola, F. M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42784-9 · Cited by 37

Downregulation of RIG-I mediated by ITGB3/c-SRC/STAT3 signaling confers resistance to interferon-α-induced apoptosis in tumor-repopulating cells of melanoma

Li, Y., Song, Y., Li, P., Li, M., Wang, H., Xu, T., Yu, X., Yu, Y., Tai, Y., Chen, P., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000111 · Cited by 38

Association between Inflammation and Function of Cell Adhesion Molecules Influence on Gastrointestinal Cancer Development

Huang, H., Chang, C., Wang, C., & Lin, K. (2021) · Cells · doi:10.3390/cells10010067 · Cited by 37

Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications

Cabo, M., Offringa, R., Zitvogel, L., Kroemer, G., Muntasell, A., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1371896 · Cited by 37

circREEP3 Drives Colorectal Cancer Progression via Activation of FKBP10 Transcription and Restriction of Antitumor Immunity

Chen, Z., He, L., Zhao, L., Zhang, G., Wang, Z., Zhu, P., & Liu, B. (2022) · Advanced Science · doi:10.1002/advs.202105160 · Cited by 37

The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy

Maiorano, B. A., Lorusso, D., Maiorano, M. F. P., Ciardiello, D., Parrella, P., Petracca, A., Cormio, G., & Maiello, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073871 · Cited by 39

Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation

Fabian, K. P., Kowalczyk, J. T., Reynolds, S. T., & Hodge, J. W. (2022) · Cells · doi:10.3390/cells11233826 · Cited by 37

Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinoma

Tanaka, T., Masuda, A., Inoue, J., Hamada, T., Ikegawa, T., Toyama, H., Sofue, K., Shiomi, H., Sakai, A., Kobayashi, T., et al. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-022-01939-8 · Cited by 36

Chiral coordination polymer nanowires boost radiation-induced in situ tumor vaccination

Huang, Z., Gu, R., Huang, S., Chen, Q., Yan, J., Cui, X., Jiang, H., Yao, D., Shen, C., Su, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48423-w · Cited by 36

Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity

Mosaheb, M., Dobrikova, E. Y., Brown, M. C., Yang, Y., Cable, J. M., Okada, H., Nair, S. K., Bigner, D. D., Ashley, D. M., & Gromeier, M. (2020) · Nature Communications · doi:10.1038/s41467-019-13939-z · Cited by 36

Nanomedicine-mediated alteration of the pharmacokinetic profile of small molecule cancer immunotherapeutics

Herck, S. V., & Geest, B. G. D. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0425-3 · Cited by 36

The Relationship Between Protein S-Nitrosylation and Human Diseases: A Review

Zhang, Y., Deng, Y., Yang, X., Xue, H., & Lang, Y. (2020) · Neurochemical Research · doi:10.1007/s11064-020-03136-6 · Cited by 36

Photothermal Therapy Combined with Neoantigen Cancer Vaccination for Effective Immunotherapy against Large Established Tumors and Distant Metastasis

Nam, J., Son, S., Park, K. S., & Moon, J. J. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100093 · Cited by 36

Lenvatinib- and vadimezan-loaded synthetic high-density lipoprotein for combinational immunochemotherapy of metastatic triple-negative breast cancer

Zheng, C., Zhang, W., Wang, J., Zhai, Y., Xiong, F., Cai, Y., Gong, X., Zhu, B., Zhu, H. H., Wang, H., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.021 · Cited by 36

A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyIC RNA

Carson, C. S., Becker, K. W., Garland, K. M., Pagendarm, H. M., Stone, P. T., Arora, K., Wang-Bishop, L., Baljon, J. J., Cruz, L. D., Joyce, S., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.020 · Cited by 36

Skin cancers under Janus kinase inhibitors: A World Health Organization drug safety database analysis

Jalles, C., Lepelley, M., Mouret, S., Charles, J., Leccia, M. ‐., & Trabelsi, S. (2022) · Therapies · doi:10.1016/j.therap.2022.04.005 · Cited by 36

Module Analysis Captures Pancancer Genetically and Epigenetically Deregulated Cancer Driver Genes for Smoking and Antiviral Response

Champion, M., Brennan, K., Croonenborghs, T., Gentles, A. J., Pochet, N. L. M. M., & Gevaert, O. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.11.028 · Cited by 39

Mechanisms of immunogenic cell death and immune checkpoint blockade therapy

Lin, R. A., Lin, J. K., & Lin, S. (2021) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12375 · Cited by 38

Harnessing type I interferon-mediated immunity to target malignant brain tumors

Lim, J., Kang, I., La, J., Ku, K. B., Kang, B. H., Kim, Y., Park, W. H., & Lee, H. K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1203929 · Cited by 35

Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression

Ramirez-Valdez, R. A., Baharom, F., Khalilnezhad, A., Fussell, S. C., Hermans, D., Schrager, A. M., Tobin, K. K. S., Lynn, G. M., Khalilnezhad, S., Ginhoux, F., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112599 · Cited by 37

Dual‐Epigenetically Relieving the MYC‐Correlated Immunosuppression via an Advanced Nano‐Radiosensitizer Potentiates Cancer Immuno‐Radiotherapy

Wang, G., Yan, J., Tian, H., Li, B., Yu, X., Feng, Y., Li, W., Zhou, S., & Dai, Y. (2024) · Advanced Materials · doi:10.1002/adma.202312588 · Cited by 35

The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy

Yang, R., & Hung, M. (2017) · Science China Life Sciences · doi:10.1007/s11427-017-9176-7 · Cited by 35

Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses

Crupi, M. J. F., Bell, J. C., & Singaravelu, R. (2019) · Stem Cells · doi:10.1002/stem.3004 · Cited by 36

Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma Tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion

Garcia‐Romero, N., Palacín-Aliana, I., Esteban-Rubio, S., Madurga, R., Rius‐Rocabert, S., Carrión-Navarro, J., Presa, J., Cuadrado‐Castano, S., Sánchez‐Gómez, P., García‐Sastre, A., et al. (2020) · Cells · doi:10.3390/cells9061405 · Cited by 35

Spatiotemporal combination of thermosensitive polypeptide fused interferon and temozolomide for post-surgical glioblastoma immunochemotherapy

Liang, P., Wang, G., Liu, X., Wang, Z., Wang, J., & Gao, W. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120447 · Cited by 35

Interferon α Induces the Apoptosis of Cervical Cancer HeLa Cells by Activating both the Intrinsic Mitochondrial Pathway and Endoplasmic Reticulum Stress-Induced Pathway

Shi, W., Cao, C., & Liu, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111832 · Cited by 35

Enhancing immunotherapy outcomes by targeted remodeling of the tumor microenvironment via combined cGAS-STING pathway strategies

Huang, M., Cha, Z., Liu, R., Lin, M., Gafoor, N. A., Kong, T., Ge, F., & Chen, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1399926 · Cited by 36

Immunosurveillance profile of oral squamous cell carcinoma and oral epithelial dysplasia through dendritic and T‐cell analysis

Pellicioli, A. C. A., Bingle, L., Farthing, P. M., Lopes, M. A., Martins, M. D., & Vargas, P. A. (2017) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12597 · Cited by 34

Cytokine‐Functionalized Synthetic Dendritic Cells for T Cell Targeted Immunotherapies

Eggermont, L. J., Hammink, R., Blank, K. G., Rowan, A. E., Tel, J., & Figdor, C. G. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800021 · Cited by 34

Sustained Type I Interferon Reinforces NK Cell–Mediated Cancer Immunosurveillance during Chronic Virus Infection

Oh, J. H., Kim, M. J., Choi, S. J., Ban, Y. H., Lee, H. K., Shin, E., Lee, K.-M., & Ha, S. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0403 · Cited by 34

p53-responsive TLR8 SNP enhances human innate immune response to respiratory syncytial virus

Menéndez, D., Snipe, J. R., Marzec, J. M., Innes, C. L., Polack, F. P., Caballero, M. T., Schurman, S. H., Kleeberger, S. R., & Resnick, M. A. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128626 · Cited by 35

Pediatric cancer research: Surviving COVID‐19

Auletta, J. J., Adamson, P. C., Agin, J., Kearns, P. R., Kennedy, S., Kieran, M. W., Ludwinski, D., Knox, L., McKay, K., Rhiner, P., et al. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28435 · Cited by 35

The MEK Inhibitors Trametinib and Cobimetinib Induce a Type I Interferon Response in Human Keratinocytes

Lulli, D., Carbone, M. L., & Pastore, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102227 · Cited by 34

ATM inhibition enhance immunotherapy by activating STING signaling and augmenting MHC Class I

Li, C., Wang, B., Tu, J., Liu, C., Wang, Y., Chen, J., Huang, Y., Liu, B., & Yuan, X. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06911-3 · Cited by 35

Mitochondria-targeted manganese-based mesoporous silica nanoplatforms trigger cGAS-STING activation and sensitize anti PD-L1 therapy in triple-negative breast cancer

Zhong, N., Zu, Z., Lu, Y., Sha, X., Li, Y., Liu, Y., Lu, S., Luo, X., Zhou, Y., Tao, J., et al. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.04.040 · Cited by 33

Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies

Aitken, A. S., Roy, D. G., & Bourgeois‐Daigneault, M. (2017) · Biomedicines · doi:10.3390/biomedicines5010003 · Cited by 35

STIM1 and STIM2 Mediate Cancer-Induced Inflammation in T Cell Acute Lymphoblastic Leukemia

Fleur-Lominy, S. S., Maus, M., Vaeth, M., Lange, I., Zee, I., Suh, D. Y., Liu, C.-J., Wu, X., Tikhonova, A. N., Aifantis, I., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.030 · Cited by 36

Peritumoral administration of IFNβ upregulated mesenchymal stem cells inhibits tumor growth in an orthotopic, immunocompetent rat glioma model

Mao, J., Cao, M., Zhang, F., Zhang, J., Duan, X., Lu, L., Yang, Z., Zhang, X., Zhu, W., Zhang, Q., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000164 · Cited by 33

CBX3 Promotes Gastric Cancer Progression and Affects Factors Related to Immunotherapeutic Responses

Lin, H., Lian, J., Xia, L., Guan, G., & You, J. (2020) · Cancer Management and Research · doi:10.2147/cmar.s271807 · Cited by 36

Tumor-derived extracellular vesicles regulate tumor-infiltrating regulatory T cells via the inhibitory immunoreceptor CD300a

Nakazawa, Y., Nishiyama, N., Koizumi, H., Kanemaru, K., Nakahashi-Oda, C., & Shibuya, A. (2021) · eLife · doi:10.7554/elife.61999 · Cited by 33

Inhibition of Proteasome Activity Induces Aggregation of IFIT2 in the Centrosome and Enhances IFIT2-Induced Cell Apoptosis

Chen, L., Liu, S., Xu, F. L., Kong, Y., Wan, L., Zhang, Y., & Zhang, Z. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.17236 · Cited by 33

TRIMming Type I Interferon-Mediated Innate Immune Response in Antiviral and Antitumor Defense

Wang, L., & Ning, S. (2021) · Viruses · doi:10.3390/v13020279 · Cited by 34

Single-nucleus and spatial transcriptomics of archival pancreatic cancer reveals multi-compartment reprogramming after neoadjuvant treatmentPreprint

Hwang, W. L., Jagadeesh, K. A., Guo, J. A., Hoffman, H. I., Yadollahpour, P., Mohan, R. R., Drokhlyansky, E., Wittenberghe, N. V., Ashenberg, O., Farhi, S. L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.25.267336 · Cited by 35

Magnetic nanoparticles enhance the cellular immune response of dendritic cell tumor vaccines by realizing the cytoplasmic delivery of tumor antigens

Huang, L., Liu, Z., Wu, C., Lin, J., & Liu, N. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10400 · Cited by 32

Interferon restores replication fork stability and cell viability in BRCA-defective cells via ISG15

Moro, R. N., Biswas, U., Kharat, S. S., Duzanic, F. D., Das, P., Stavrou, M., Raso, M. C., Freire, R., Chaudhuri, A. R., Sharan, S. K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41801-w · Cited by 35

Synthetic cationic helical polypeptides for the stimulation of antitumour innate immune pathways in antigen-presenting cells

Lee, D., Huntoon, K. M., Wang, Y., Kang, M., Lü, Y., Jeong, S. D., Link, T. M., Gallup, T. D., Qie, Y., Li, X., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01194-7 · Cited by 32

The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy

Li, G., Che, X., Wang, S., Liu, D., Xie, D., Jiang, B., Zheng, Z., Xu, Z., & Wu, G. (2025) · Annals of Medicine · doi:10.1080/07853890.2024.2447403 · Cited by 37

Collapse of the Plasmacytoid Dendritic Cell Compartment in Advanced Cutaneous Melanomas by Components of the Tumor Cell Secretome

Vescovi, R., Monti, M., Moratto, D., Paolini, L., Consoli, F., Gatta, L. B., Melocchi, L., Calza, S., Chiudinelli, M., Rossi, G., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0141 · Cited by 32

Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma

Zhao, J., Zhou, Z.-Q., Wang, P., Chen, C., Liu, Y., Pan, Q., Zhu, Q., Tang, Y., Weng, D., & Xia, J. (2018) · Cancer Management and Research · doi:10.2147/cmar.s181949 · Cited by 32

Temperature-triggered micellization of interferon alpha-diblock copolypeptide conjugate with enhanced stability and pharmacology

Wang, Z., Guo, J., Liu, X., Sun, J., & Gao, W. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.065 · Cited by 32

Depletion of DNA Polymerase Theta Inhibits Tumor Growth and Promotes Genome Instability through the cGAS-STING-ISG Pathway in Esophageal Squamous Cell Carcinoma

Li, J., Ko, J. M. Y., Dai, W., Yu, V. Z., Ng, H. Y., Hoffmann, J., & Lung, M. L. (2021) · Cancers · doi:10.3390/cancers13133204 · Cited by 35

Interferon Signaling in Estrogen Receptor–positive Breast Cancer: A Revitalized Topic

Fu, X., Angelis, C. D., & Schiff, R. (2021) · Endocrinology · doi:10.1210/endocr/bqab235 · Cited by 33

Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types

Budczies, J., Kluck, K., Beck, S., Ourailidis, I., Allgäuer, M., Menzel, M., Kazdal, D. N., Perkhofer, L., Kleger, A., Schirmacher, P., et al. (2022) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.271 · Cited by 34

Hsp90β inhibition upregulates interferon response and enhances immune checkpoint blockade therapy in murine tumors

Rahmy, S., Mishra, S. J., Murphy, S. P., Blagg, B. S. J., & Lü, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1005045 · Cited by 32

Vertical transmission of hepatitis E virus in pregnant rhesus macaques

Yu, W., Hao, X., Li, Y., Yang, C., Li, Y., He, Z., & Huang, F. (2020) · Scientific Reports · doi:10.1038/s41598-020-74461-7 · Cited by 32

ASCC3 promotes the immunosuppression and progression of non-small cell lung cancer by impairing the type I interferon response via CAND1-mediated ubiquitination inhibition of STAT3

Ao, Y.-Q., Gao, J., Jin, C., Wang, S., Zhang, L., Deng, J., Chen, Z.-W., Wang, H., Jiang, J.-H., & Ding, J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007766 · Cited by 31

Influence of Microbiota on Tumor Immunotherapy

Yu, X., Li, W., Li, Z., Wu, Q., & Sun, S. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.91771 · Cited by 33

Host Innate Immunity against Hepatitis E Virus and Viral Evasion Mechanisms

Kang, S., & Myoung, J. (2017) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1708.08045 · Cited by 31

One-month zero-order sustained release and tumor eradication after a single subcutaneous injection of interferon alpha fused with a body-temperature-responsive polypeptide

Wang, Z., Guo, J., Ning, J., Feng, X., Liu, X., Sun, J., Chen, X., Lu, F., & Gao, W. (2018) · Biomaterials Science · doi:10.1039/c8bm01096j · Cited by 31

Type I interferons and dendritic cells in cancer immunotherapy

(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.06.001 · Cited by 124

The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation

Musella, M., Galassi, C., Manduca, N., & Sistigu, A. (2021) · Biology · doi:10.3390/biology10090856 · Cited by 45

Type I Interferons and Natural Killer Cell Regulation in Cancer

Müller, L., Aigner, P., & Stoiber, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00304 · Cited by 173

The added value of type I interferons to cytotoxic treatments of cancer

Bracci, L., Sistigu, A., Proietti, E., & Moschella, F. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.008 · Cited by 20

Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications

Musella, M., Manic, G., Maria, R. D., Vitale, I., & Sistigu, A. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1314424 · Cited by 147